SCHEMBL4693833

SCHEMBL4693833

COc1cccc(C(O)(Br)C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
PARP1 P09874 1/20 0.46
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
EDNRB P24530 1/20 0.44
EDNRA P25101 1/20 0.44
KIF11 P52732 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NLRP3 Q96P20 1/20 0.43
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
STAT1 P42224 1/20 0.42
HTT P42858 1/20 0.42
PDK1 Q15118 1/20 0.42
PDK2 Q15119 1/20 0.42
PDK3 Q15120 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4958167 0.84 CES2 (0.50) CES2CES1LMNAKDM4EPOLB
SCHEMBL2797715 0.84 CES2 (0.50) CES2CES1LMNAKDM4EPOLB
SCHEMBL6288739 0.83 CES2 (0.49) CES2CES1LMNAKDM4EPOLB
SCHEMBL1368545 0.83 CES2 (0.49) CES2CES1LMNAKDM4EPOLB
SCHEMBL8615954 0.81 PARP1 (0.49) CES2CES1LMNAKDM4EPOLB
SCHEMBL14166571 0.81 CYP2C9 (0.49) CES2CES1LMNAPARP1NPC1
SCHEMBL1356271 0.81 AKR1C3 (0.52) CES2CES1LMNAKDM4EPOLB
SCHEMBL4138316 0.80 ALDH1A1 (0.46) CES2CES1LMNAKDM4EPARP1
SCHEMBL9654996 0.79 PARP1 (0.50) CES2CES1LMNAKDM4EPOLB
SCHEMBL22285693 0.79 CES2 (0.49) CES2CES1LMNAKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569935-B1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS NOVEXEL (FR) 2008-08-20 EP disclosed
EP-1798231-A2 Intermediate products for the preparation of antibacterial compounds NOVEXEL (FR) 2007-06-20 EP disclosed
EP-1399444-B1 NOVEL HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-BACTERIAL AGENTS NOVEXEL (FR) 2007-04-11 EP disclosed
EP-1569935-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS Aventis Pharma S.A. (FR) 2005-09-07 EP disclosed
WO-2004052891-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-06-24 WO disclosed
EP-1399444-A2 NOVEL HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-BACTERIAL AGENTS Aventis Pharma S.A. (FR) 2004-03-24 EP disclosed
WO-2002100860-A2 HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-BACTERIAL AGENTS AVENTIS PHARMA S.A. (FR) 2002-12-19 WO disclosed